RaniPill's billion-dollar Chugai deal and fresh $60M cash? That's rocket fuel! 🚀 The chart just exploded from $1.55 to $2.20 on monster volume. The 9-day WMA is screaming past the 21-day, and the RSI is strong but not overheated. This is a classic news-driven breakout. All signs point to BUY. #PennyStockPlay

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-106, a basal insulin for the treatment of type 2 diabetes. The company was incorporated in 2012 and is headquartered in San Jose, California.

Rani Therapeutics Holdings, Inc. RANI: 1.59 USD

Bullish views